| Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis SR Flaxman, RRA Bourne, S Resnikoff, P Ackland, T Braithwaite, ... The Lancet Global Health 5 (12), e1221-e1234, 2017 | 3584 | 2017 |
| Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and meta-analysis RRA Bourne, SR Flaxman, T Braithwaite, MV Cicinelli, A Das, JB Jonas, ... The Lancet Global Health 5 (9), e888-e897, 2017 | 2715 | 2017 |
| Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion: twelve-month study results JA Haller, F Bandello, R Belfort Jr, MS Blumenkranz, M Gillies, J Heier, ... Ophthalmology 118 (12), 2453-2460, 2011 | 924 | 2011 |
| Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double … JS Heier, AM Khanani, CQ Ruiz, K Basu, PJ Ferrone, C Brittain, ... The Lancet 399 (10326), 729-740, 2022 | 476 | 2022 |
| Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1 Verteporfin in Photodynamic Therapy Study Group Ophthalmology 108 (5), 841-852, 2001 | 439 | 2001 |
| Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study U Schmidt-Erfurth, GE Lang, FG Holz, RO Schlingemann, P Lanzetta, ... Ophthalmology 121 (5), 1045-1053, 2014 | 438 | 2014 |
| Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials P Mitchell, JF Korobelnik, P Lanzetta, FG Holz, C Pruente, ... British Journal of Ophthalmology 94 (1), 2-13, 2010 | 387 | 2010 |
| Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two … CC Wykoff, F Abreu, AP Adamis, K Basu, DA Eichenbaum, Z Haskova, ... The Lancet 399 (10326), 741-755, 2022 | 385 | 2022 |
| Treat-and-extend regimens with anti-VEGF agents in retinal diseases: a literature review and consensus recommendations KB Freund, JF Korobelnik, R Devenyi, C Framme, J Galic, E Herbert, ... Retina 35 (8), 1489-1506, 2015 | 310 | 2015 |
| Myopic choroidal neovascularisation: current concepts and update on clinical management TY Wong, K Ohno-Matsui, N Leveziel, FG Holz, TY Lai, HG Yu, P Lanzetta, ... British Journal of Ophthalmology 99 (3), 289-296, 2015 | 202 | 2015 |
| Management of retinal vein occlusion–consensus document G Coscas, A Loewenstein, A Augustin, F Bandello, M Battaglia Parodi, ... Ophthalmologica 226 (1), 4-28, 2011 | 199 | 2011 |
| Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results M Larsen, U Schmidt-Erfurth, P Lanzetta, S Wolf, C Simader, E Tokaji, ... Ophthalmology 119 (5), 992-1000, 2012 | 192 | 2012 |
| Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti–vascular endothelial growth factor therapy of macular diseases P Lanzetta, A Loewenstein, Vision Academy Steering Committee Graefe's Archive for Clinical and Experimental Ophthalmology 255, 1259-1273, 2017 | 177 | 2017 |
| Ocular findings in COVID‐19 patients: a review of direct manifestations and indirect effects on the eye F Bertoli, D Veritti, C Danese, F Samassa, V Sarao, N Rassu, T Gambato, ... Journal of ophthalmology 2020 (1), 4827304, 2020 | 172 | 2020 |
| Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial AM Khanani, SS Patel, G Staurenghi, R Tadayoni, CJ Danzig, ... The Lancet 402 (10411), 1449-1458, 2023 | 171 | 2023 |
| Diabetic macular edema F Bandello, M Battaglia Parodi, P Lanzetta, A Loewenstein, P Massin, ... Dev Ophthalmol 58 (58), 102-38, 2017 | 164 | 2017 |
| Intravitreal steroids for the treatment of retinal diseases V Sarao, D Veritti, F Boscia, P Lanzetta The Scientific World Journal 2014 (1), 989501, 2014 | 157 | 2014 |
| Nonvisible subthreshold micropulse diode laser (810 nm) treatment of central serous chorioretinopathy: a pilot study P Lanzetta, F Furlan, L Morgante, D Veritti, F Bandello European journal of ophthalmology 18 (6), 934-940, 2008 | 156 | 2008 |
| Method and apparatus for real-time detection, control and recording of sub-clinical therapeutic laser lesions during ocular laser photocoagulation P Lanzetta, G Dorin US Patent 6,540,391, 2003 | 148 | 2003 |
| Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant WS Yeh, JA Haller, P Lanzetta, BD Kuppermann, TY Wong, P Mitchell, ... Ophthalmology 119 (6), 1190-1198, 2012 | 142 | 2012 |
